CN104470500A - 包含1-(6-{[6-(4-氟苯基)[1,2,4]三唑并[4,3-b]哒嗪-3-基]硫基}-1,3-苯并噻唑-2-基)-3-(2-吗啉-4-基乙基)尿素化合物的抗肿瘤组合物 - Google Patents

包含1-(6-{[6-(4-氟苯基)[1,2,4]三唑并[4,3-b]哒嗪-3-基]硫基}-1,3-苯并噻唑-2-基)-3-(2-吗啉-4-基乙基)尿素化合物的抗肿瘤组合物 Download PDF

Info

Publication number
CN104470500A
CN104470500A CN201380037070.8A CN201380037070A CN104470500A CN 104470500 A CN104470500 A CN 104470500A CN 201380037070 A CN201380037070 A CN 201380037070A CN 104470500 A CN104470500 A CN 104470500A
Authority
CN
China
Prior art keywords
compound
pharmaceutical composition
aqueous liquid
liquid pharmaceutical
ylethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380037070.8A
Other languages
English (en)
Chinese (zh)
Inventor
J-R·奥塞林
S·阿萨杜里安
T·贝纳尔德
H·古劳乌伊克
A·马蒂厄
M-T·佩拉基亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN104470500A publication Critical patent/CN104470500A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CN201380037070.8A 2012-07-12 2013-07-11 包含1-(6-{[6-(4-氟苯基)[1,2,4]三唑并[4,3-b]哒嗪-3-基]硫基}-1,3-苯并噻唑-2-基)-3-(2-吗啉-4-基乙基)尿素化合物的抗肿瘤组合物 Pending CN104470500A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305840 2012-07-12
EP12305840.6 2012-07-12
PCT/EP2013/064741 WO2014009500A1 (en) 2012-07-12 2013-07-11 Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea

Publications (1)

Publication Number Publication Date
CN104470500A true CN104470500A (zh) 2015-03-25

Family

ID=48782350

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380037070.8A Pending CN104470500A (zh) 2012-07-12 2013-07-11 包含1-(6-{[6-(4-氟苯基)[1,2,4]三唑并[4,3-b]哒嗪-3-基]硫基}-1,3-苯并噻唑-2-基)-3-(2-吗啉-4-基乙基)尿素化合物的抗肿瘤组合物

Country Status (25)

Country Link
US (1) US20150119391A1 (enExample)
EP (1) EP2872119A1 (enExample)
JP (1) JP2015525754A (enExample)
KR (1) KR20150030761A (enExample)
CN (1) CN104470500A (enExample)
AR (1) AR091727A1 (enExample)
AU (1) AU2013288676A1 (enExample)
BR (1) BR112015000497A2 (enExample)
CA (1) CA2878500A1 (enExample)
CL (1) CL2015000074A1 (enExample)
CO (1) CO7160069A2 (enExample)
CR (1) CR20150005A (enExample)
EA (1) EA201590199A1 (enExample)
HK (1) HK1209642A1 (enExample)
IL (1) IL236662A0 (enExample)
IN (1) IN2015KN00075A (enExample)
MA (1) MA37753B1 (enExample)
MX (1) MX2015000532A (enExample)
PH (1) PH12015500060A1 (enExample)
SG (1) SG11201500123XA (enExample)
TN (1) TN2015000011A1 (enExample)
TW (1) TW201402121A (enExample)
UY (1) UY34909A (enExample)
WO (1) WO2014009500A1 (enExample)
ZA (1) ZA201500129B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022414970A1 (en) * 2021-12-15 2024-06-27 Sillajen, Inc. Pharmaceutical compositions comprising modified beta-cyclodextrins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1258220A (zh) * 1997-06-05 2000-06-28 詹森药业有限公司 含环糊精的药物组合物
CN1479610A (zh) * 2000-12-11 2004-03-03 ʥŵ��-�ϳ�ʵ���ҹ�˾ 肠胃道外给药的多恩达隆医药组合物
WO2009056692A2 (fr) * 2007-08-09 2009-05-07 Sanofi-Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
WO2010089508A1 (fr) * 2009-02-06 2010-08-12 Sanofi-Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004206842A1 (en) * 2003-01-14 2004-08-05 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
BRPI0908077A2 (pt) * 2008-02-28 2015-08-25 Takeda Pharmaceutical Composição farmacêutica, métodos para prevenir ou tratar doenças, e para melhorar solubilidade em água de um composto, um sal ou uma pró-droga do mesmo
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1258220A (zh) * 1997-06-05 2000-06-28 詹森药业有限公司 含环糊精的药物组合物
CN1479610A (zh) * 2000-12-11 2004-03-03 ʥŵ��-�ϳ�ʵ���ҹ�˾ 肠胃道外给药的多恩达隆医药组合物
WO2009056692A2 (fr) * 2007-08-09 2009-05-07 Sanofi-Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
WO2010089508A1 (fr) * 2009-02-06 2010-08-12 Sanofi-Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met

Also Published As

Publication number Publication date
EP2872119A1 (en) 2015-05-20
CL2015000074A1 (es) 2015-06-12
TW201402121A (zh) 2014-01-16
WO2014009500A1 (en) 2014-01-16
EA201590199A1 (ru) 2015-05-29
CO7160069A2 (es) 2015-01-15
MA37753A2 (fr) 2016-06-30
JP2015525754A (ja) 2015-09-07
MX2015000532A (es) 2015-05-15
UY34909A (es) 2013-11-29
BR112015000497A2 (pt) 2017-06-27
SG11201500123XA (en) 2015-02-27
ZA201500129B (en) 2015-12-23
MA37753B1 (fr) 2019-04-30
AR091727A1 (es) 2015-02-25
CR20150005A (es) 2015-04-06
MA37753A3 (fr) 2018-05-31
CA2878500A1 (en) 2014-01-16
PH12015500060A1 (en) 2015-03-02
AU2013288676A1 (en) 2015-02-05
IL236662A0 (en) 2015-02-26
US20150119391A1 (en) 2015-04-30
TN2015000011A1 (en) 2016-06-29
KR20150030761A (ko) 2015-03-20
IN2015KN00075A (enExample) 2015-07-31
HK1209642A1 (en) 2016-04-08

Similar Documents

Publication Publication Date Title
JP5449784B2 (ja) 抗癌用途のためのドキソルビシン製剤
JP6695003B2 (ja) 癌のための併用療法
US8709419B2 (en) Combination therapy
US10975146B2 (en) Interleukin-1 inhibition for combination treatment of pancreatic cancer
TW201941773A (zh) 用於治療非小細胞肺癌之奧希替尼
CN114945358A (zh) 用于纳米颗粒组合物的生物标记
TW201701880A (zh) 改善持續釋放藥物治療之藥物動力學及治療指數之方法
CN113226320A (zh) Mdm2抑制剂的延长的低剂量方案
TW202123935A (zh) 用於奈米粒子組合物之生物標記
Quintero Aldana et al. First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial
KR20210126654A (ko) 암 치료
EP2678011B1 (en) Antitumoral combination comprising cabazitaxel and cisplatin
CN104470500A (zh) 包含1-(6-{[6-(4-氟苯基)[1,2,4]三唑并[4,3-b]哒嗪-3-基]硫基}-1,3-苯并噻唑-2-基)-3-(2-吗啉-4-基乙基)尿素化合物的抗肿瘤组合物
TW202034955A (zh) 使用免疫調節治療癌症之新穎方法
WO2022247846A1 (zh) 多西他赛白蛋白组合物和免疫检查点抑制剂的组合及用途
CN108135878A (zh) 卡巴他赛及其治疗癌症的用途
WO2025103408A1 (zh) 治疗alk阳性或ros1阳性的非小细胞肺癌的方法
HK40083164A (en) Combination of docetaxel albumin composition and immune checkpoint inhibitor and use thereof
Sequist et al. A phase 1b study of osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small cell lung cancer after progression on EGFR-tyrosine kinase inhibitors
Liu et al. Low-dose apatinib in subjects with renal impairment: A pharmacokinetics study
CN119326765A (zh) 化合物用于治疗非小细胞肺癌的用途
WO2023196329A1 (en) Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer
WO2024120520A1 (zh) 喹诺林化合物治疗小细胞肺癌的用途
HK40083164B (zh) 多西他赛白蛋白组合物和免疫检查点抑制剂的组合及用途
TW201542201A (zh) 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）於具有轉移性ｎｓｃｌｃ發展病患中經多西紫杉醇為基礎治療之後的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150325